- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00764790
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35244
- GSK Investigational Site
-
Birmingham, Alabama, Estados Unidos, 35205
- GSK Investigational Site
-
Dothan, Alabama, Estados Unidos, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, Estados Unidos, 72019
- GSK Investigational Site
-
Conway, Arkansas, Estados Unidos, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, Estados Unidos, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, Estados Unidos, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, Estados Unidos, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, Estados Unidos, 92647
- GSK Investigational Site
-
Long Beach, California, Estados Unidos, 90806
- GSK Investigational Site
-
Paramount, California, Estados Unidos, 90723
- GSK Investigational Site
-
Sacramento, California, Estados Unidos, 95816
- GSK Investigational Site
-
San Francisco, California, Estados Unidos, 94102
- GSK Investigational Site
-
West Covina, California, Estados Unidos, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, Estados Unidos, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, Estados Unidos, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, Estados Unidos, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, Estados Unidos, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, Estados Unidos, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Estados Unidos, 67005
- GSK Investigational Site
-
Newton, Kansas, Estados Unidos, 67114
- GSK Investigational Site
-
Wichita, Kansas, Estados Unidos, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Estados Unidos, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Estados Unidos, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, Estados Unidos, 71111
- GSK Investigational Site
-
Metairie, Louisiana, Estados Unidos, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, Estados Unidos, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, Estados Unidos, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Estados Unidos, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Estados Unidos, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, Estados Unidos, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, Estados Unidos, 28607
- GSK Investigational Site
-
Cary, North Carolina, Estados Unidos, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, Estados Unidos, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, Estados Unidos, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, Estados Unidos, 45245
- GSK Investigational Site
-
Cleveland, Ohio, Estados Unidos, 44121
- GSK Investigational Site
-
Dayton, Ohio, Estados Unidos, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, Estados Unidos, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, Estados Unidos, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, Estados Unidos, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, Estados Unidos, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, Estados Unidos, 37043
- GSK Investigational Site
-
Jackson, Tennessee, Estados Unidos, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, Estados Unidos, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Estados Unidos, 76135
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77055
- GSK Investigational Site
-
San Angelo, Texas, Estados Unidos, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, Estados Unidos, 84010
- GSK Investigational Site
-
Layton, Utah, Estados Unidos, 84041
- GSK Investigational Site
-
Murray, Utah, Estados Unidos, 84107
- GSK Investigational Site
-
Provo, Utah, Estados Unidos, 84604
- GSK Investigational Site
-
Roy, Utah, Estados Unidos, 84067
- GSK Investigational Site
-
South Jordan, Utah, Estados Unidos, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, Estados Unidos, 22015
- GSK Investigational Site
-
-
-
-
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Mexico, México, 6720
- GSK Investigational Site
-
Mexico city, México, 04530
- GSK Investigational Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwán, 104
- GSK Investigational Site
-
Taipei, Taiwán
- GSK Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Experimental: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Comparador activo: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Periodo de tiempo: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Number of Subjects Who Seroconverted
Periodo de tiempo: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Seroprotected Subjects
Periodo de tiempo: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Seroconversion Factor
Periodo de tiempo: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
|
Number of Subjects Reporting Solicited Local Symptoms
Periodo de tiempo: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Solicited General Symptoms
Periodo de tiempo: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Periodo de tiempo: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Periodo de tiempo: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
|
Number of Subjects Reporting Rare Serious Events
Periodo de tiempo: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 111751
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Datos del estudio/Documentos
-
Especificación del conjunto de datos
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de consentimiento informado
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan de Análisis Estadístico
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de informe de caso anotado
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Informe de estudio clínico
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de datos de participantes individuales
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudio
Identificador de información: 111751Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .